Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
